DiscoverThe Lancet Infectious Diseases in conversation withLeonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile
Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile

Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile

Update: 2025-06-10
Share

Description

Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond.

Read the full article at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00233-6/fulltext?dgcid=buzzsprout_icw_podcast_10-06-25_laninf

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile

Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile

The Lancet Group